277 related articles for article (PubMed ID: 31071311)
21. Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies.
Ribeiro A; Brandão JR; Cleto E; Santos M; Borges T; Santos Silva E
GE Port J Gastroenterol; 2019 Aug; 26(5):362-369. PubMed ID: 31559327
[TBL] [Abstract][Full Text] [Related]
22. Lipodystrophies: adipose tissue disorders with severe metabolic implications.
Cortés VA; Fernández-Galilea M
J Physiol Biochem; 2015 Sep; 71(3):471-8. PubMed ID: 25833179
[TBL] [Abstract][Full Text] [Related]
23. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
24. Lipodystrophy Syndromes.
Hussain I; Garg A
Endocrinol Metab Clin North Am; 2016 Dec; 45(4):783-797. PubMed ID: 27823605
[TBL] [Abstract][Full Text] [Related]
25. Lipodystrophies in Children.
Mainieri F; Chiarelli F
Horm Res Paediatr; 2022; 95(4):305-320. PubMed ID: 35189617
[TBL] [Abstract][Full Text] [Related]
26. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.
Akinci B; Subauste A; Ajluni N; Esfandiari NH; Meral R; Neidert AH; Eraslan A; Hench R; Rus D; McKenna B; Hussain HK; Chenevert TL; Tayeh MK; Rupani AR; Innis JW; Mantzoros CS; Conjeevaram HS; Burant CL; Oral EA
Med; 2021 Jul; 2(7):814-835. PubMed ID: 35291351
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy.
Altay C; Seçil M; Adıyaman SC; Özgen Saydam B; Demir T; Akıncı G; Simsir IY; Eren E; Temeloğlu Keskin E; Demir L; Onay H; Topaloğlu H; Sarer Yürekli B; Özdemir Kutbay N; Gen R; Akıncı B
Turk J Gastroenterol; 2020 Aug; 31(8):588-595. PubMed ID: 32915147
[TBL] [Abstract][Full Text] [Related]
28. Partial lipodystrophy: Clinical presentation and treatment.
Mosbah H; Vatier C; Vigouroux C
Ann Endocrinol (Paris); 2024 Jun; 85(3):197-200. PubMed ID: 38871513
[TBL] [Abstract][Full Text] [Related]
29. Leptin treatment: facts and expectations.
Paz-Filho G; Mastronardi CA; Licinio J
Metabolism; 2015 Jan; 64(1):146-56. PubMed ID: 25156686
[TBL] [Abstract][Full Text] [Related]
30. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
DePaoli AM
J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
[TBL] [Abstract][Full Text] [Related]
31. [Recognize rare diseases by the adipose tissue : Lipodystrophy-actually simple but nevertheless often overlooked].
Wabitsch M; V Schnurbein J
Internist (Berl); 2020 Oct; 61(10):1063-1075. PubMed ID: 32930809
[TBL] [Abstract][Full Text] [Related]
32. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.
Garg A
J Clin Endocrinol Metab; 2011 Nov; 96(11):3313-25. PubMed ID: 21865368
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.
Misra A; Garg A
Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189
[TBL] [Abstract][Full Text] [Related]
34. Leptin in congenital and HIV-associated lipodystrophy.
Tsoukas MA; Farr OM; Mantzoros CS
Metabolism; 2015 Jan; 64(1):47-59. PubMed ID: 25267014
[TBL] [Abstract][Full Text] [Related]
35. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.
Machado MV; Coutinho J; Carepa F; Costa A; Proença H; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1166-72. PubMed ID: 22735605
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and treatment of lipodystrophy: a step-by-step approach.
Araújo-Vilar D; Santini F
J Endocrinol Invest; 2019 Jan; 42(1):61-73. PubMed ID: 29704234
[TBL] [Abstract][Full Text] [Related]
37. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
[TBL] [Abstract][Full Text] [Related]
38. Complications of lipodystrophy syndromes.
Akinci G; Celik M; Akinci B
Presse Med; 2021 Nov; 50(3):104085. PubMed ID: 34728268
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease and HIV infection.
Vallet-Pichard A; Mallet V; Pol S
Semin Liver Dis; 2012 May; 32(2):158-66. PubMed ID: 22760655
[TBL] [Abstract][Full Text] [Related]
40. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.
Javor ED; Moran SA; Young JR; Cochran EK; DePaoli AM; Oral EA; Turman MA; Blackett PR; Savage DB; O'Rahilly S; Balow JE; Gorden P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3199-207. PubMed ID: 15240593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
